Imaging integrin αvβ3 on blood vessels with 111In-RGD2 in head and neck tumor xenografts

Journal of Nuclear Medicine

Volumn 55, Issue 2, 2014, Pages 281-286

  Terry, Samantha Y A ^a   Abiraj, Keelara ^b   Frielink, Cathelijne ^a   Van Dijk, Laura K ^a   Bussink, Johan ^a   Oyen, Wim J ^a   Boerman, Otto C ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Angiogenesis; Dimeric RGD; Head and neck carcinoma; SPECT imaging

Indexed keywords

INDIUM ARGINYLGLYCYLASPARTYLSERINE IN 111; RADIOPHARMACEUTICAL AGENT; TETRAXETAN; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; ARGINYL-GLYCYL-ASPARTIC ACID; ARGINYLGLYCYLASPARTIC ACID; INDIUM; OLIGOPEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CONTROLLED STUDY; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; ISOTOPE LABELING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE DISTRIBUTION; RADIATION DOSE ESCALATION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SQUAMOUS CELL CARCINOMA; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; ANGIOGENESIS; ANIMAL; BAGG ALBINO MOUSE; BLOOD VESSEL; CANCER TRANSPLANTATION; CHEMISTRY; COMPUTER ASSISTED TOMOGRAPHY; DIMERIC RGD; HEAD AND NECK TUMOR; INTEGRIN ΑVΒ3; METABOLISM; METHODOLOGY; NEOVASCULARIZATION (PATHOLOGY); SCINTISCANNING; SPECT IMAGING; TUMOR CELL LINE; VASCULARIZATION;

ANGIOGENESIS; DIMERIC RGD; HEAD AND NECK CARCINOMA; INTEGRIN ΑVΒ3; SPECT IMAGING;

ANIMALS; BLOOD VESSELS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; FEMALE; HEAD AND NECK NEOPLASMS; IMMUNOHISTOCHEMISTRY; INDIUM RADIOISOTOPES; INTEGRIN ALPHAVBETA3; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; OLIGOPEPTIDES; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84897929232     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.129668     Document Type: Article

References (38)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144: 646-674.
2. Weis SM, Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med. 2011;17: 1359-1370.
3. Weis SM, Cheresh DA. aV integrins in angiogenesis and cancer. Cold Spring Harb Perspect Med. 2011;1: a006478.
4. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003;3: 401-410.
5. Ruoslahti E, Pierschbacher MD. New perspectives in cell adhesion: RGD and integrins. Science. 1987;238: 491-497.
6. Brakebusch C, Bouvard D, Stanchi F, Sakai T, Fassler R. Integrins in invasive growth. J Clin Invest. 2002;109: 999-1006.
7. Mas-Moruno C, Rechenmacher F, Kessler H. Cilengitide: the first anti-Angiogenic small molecule drug candidate design, synthesis and clinical evaluation. Anticancer Agents Med Chem. 2010;10: 753-768.
8. Samant RS, Shevde LA. Recent advances in anti-Angiogenic therapy of cancer. Oncotarget. 2011;2: 122-134.
9. O'Connor JP, Jackson A, Parker GJ, Roberts C, Jayson GC. Dynamic contrastenhanced MRI in clinical trials of antivascular therapies. Nat Rev Clin Oncol. 2012;9: 167-177.
10. Desar IM, van Herpen CM, van Laarhoven HW, Barentsz JO, Oyen WJ, van der Graaf WT. Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy. Cancer Treat Rev. 2009;35: 309-321.
11. Dijkgraaf I, Boerman OC. Radionuclide imaging of tumor angiogenesis. Cancer Biother Radiopharm. 2009;24: 637-647.
12. 3 positive glioma with a novel RGD dimer probe and the impact of antiangiogenic agent (Endostar) on its tumor uptake. Cancer Lett. 2013;335: 75-80.
13. 3-integrin and avb5-integrin imaging agent. J Nucl Med. 2011;52: 424-430.
14. Gurrath M, Muller G, Kessler H, Aumailley M, Timpl R. Conformation/activity studies of rationally designed potent anti-Adhesive RGD peptides. Eur J Biochem. 1992;210: 911-921.
15. 3 integrin by multimerisation of RGD peptides. Eur J Nucl Med Mol Imaging. 2007;34: 267-273.
16. 99mTc-RAFTRGD. J Nucl Cardiol. 2010;17: 435-443.
17. 18F-labeled dimeric RGD peptide. Contrast Media Mol Imaging. 2013;8: 238-245.
18. 3 integrin binding peptides in a nude mouse model. Cancer Res. 2002;62: 6146-6151.
19. 68Ga-labelled mono-, di-And tetrameric RGD peptides. Eur J Nucl Med Mol Imaging. 2011;38: 128-137.
20. 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 2001;61: 1781-1785.
21. Ljungkvist AS, Bussink J, Kaanders JH, et al. Hypoxic cell turnover in different solid tumor lines. Int J Radiat Oncol Biol Phys. 2005;62: 1157-1168.
22. Stegeman H, Kaanders JH, van der Kogel AJ, et al. Predictive value of hypoxia, proliferation and tyrosine kinase receptors for EGFR-inhibition and radiotherapy sensitivity in head and neck cancer models. Radiother Oncol. 2013;106: 383-389.
23. van der Have F, Vastenhouw B, Ramakers RM, et al. U-SPECT-II: an ultra-highresolution device for molecular small-Animal imaging. J Nucl Med. 2009;50: 599-605.
24. 3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res. 2007;13: 6610-6616.
25. Sivolapenko GB, Skarlos D, Pectasides D, et al. Imaging of metastatic melanoma utilising a technetium-99m labelled RGD-containing synthetic peptide. Eur J Nucl Med. 1998;25: 1383-1389.
26. 18F-galacto-RGD in cancer patients. J Nucl Med. 2005;46: 1333-1341.
27. 18F-AH111585, to determine changes in tumor vascularity after antitumor therapy. J Nucl Med. 2009;50: 116-122.
28. 99mTc-labeled glucosamino RGD and effect of paclitaxel therapy. J Nucl Med. 2006;47: 2000-2007.
29. 18F] Galacto-RGD. PLoS Med. 2005;2: e70.
30. 111In-labeled RGD peptide. Nucl Med Biol. 2007;34: 29-35.
31. Janssen M, Oyen WJ, Massuger LF, et al. Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting. Cancer Biother Radiopharm. 2002;17: 641-646.
32. 3 integrin expression. Eur J Nucl Med Mol Imaging. 2007;34: 1823-1831.
33. 3-Targeted SPECT radiotracer with high tumor uptake and favorable pharmacokinetics. Eur J Nucl Med Mol Imaging. 2009;36: 1874-1884.
34. 3 integrin expression. Eur J Nucl Med Mol Imaging. 2008;35: 1507-1515.
35. 3 expressed on both tumor cells and neovasculature. Bioconjug Chem. February 25, 2010 [Epub ahead of print].
36. 99mTc-labeled cyclic arginine-glycine-Aspartic (RGD) dimers with triglycine linkers. J Med Chem. 2008;51: 7980-7990.
37. 99mTc-labeled cyclic RGD dimers with PEG(4) linkers. Mol Pharm. 2009;6: 231-245.
38. 99mTc-RAFT-RGD. Eur J Nucl Med Mol Imaging. 2007;34: 2037-2047.